Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Transcription Factor Drug Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for HBP1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | HBP1 Full-Length & HMG-Box Domain Protein (Also covers AXH domain); High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Available in E. coli and HEK293 expression systems. | View HBP1 Products |
| Gene Delivery | HBP1 Premade Lentivirus Particles (CMV/EF1a promoters) for stable cell line construction in ChIP, reporter assays, and functional overexpression validation. | View HBP1 Products |
| Validation Antibody | Anti-HBP1 Monoclonal Antibody; High specificity for Western Blot, IP, ChIP, and IHC. | View HBP1 Products |
| Validator | HBP1 siRNA Set (3 unique sequences) for knockdown verification and specificity controls. | View HBP1 Products |
| Related Target: CTNNB1 | β-Catenin; Wnt pathway effector repressed by HBP1; critical for co-regulatory studies. | View CTNNB1 Products |
| Related Target: AR | Androgen Receptor; Key interacting partner in prostate cancer; co-repressor complex analysis. | View AR Products |
| Related Target: MYC | c-Myc; Downstream oncogenic target negatively regulated by HBP1; proliferation control node. | View MYC Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Intracellular Target Evaluation & Localization | High-purity recombinant HBP1 (E. coli / Sf9 / HEK293) for SPR, PPI binding assays; lentivirus with CMV/EF1a for stable nuclear expression ideal for ChIP-seq validation. |
| DNA-Binding Specificity Validation | Wild-Type vs. DNA-binding domain mutant proteins (R233A/K237A) with >95% purity for EMSA and SPR selectivity assays. |
| Functional Pathway Readout & PPI Screening | Lentivirus-driven overexpression vectors to assess Wnt/beta-catenin repression; full-length HBP1 with native folding for AlphaScreen/Co-IP. |
| Lack of Functional Controls | Sequence-verified antibodies and overexpression lysates included for assay normalization; valid knockdown controls with siRNA. |
| False Positives in Knockdown | Validated siRNA set (3 distinct sequences) for specificity checks, minimizing off-target effects. |
Live HBP1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for HBP1-related therapeutics is intensifying. As a critical tumor suppressor and transcriptional repressor in the Wnt/β-catenin pathway, HBP1 downregulation correlates with poor prognosis in prostate, breast, and brain malignancies. The current R&D landscape is transitioning from observational studies to mechanistic strategies, with emerging interest in targeted protein stabilization (TPS), targeted protein degradation (PROTAC/molecular glues), epigenetic restoration, and PPI disruptors. As first-generation therapies face resistance, the next wave of R&D is targeting the stabilization or restoration of HBP1 to suppress cell cycle progression in aggressive cancers.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| PROTAC / Molecular Glue | Arvinas-style biotechs, Academic consortia, TPD firms | Prostate Cancer, Triple-Negative Breast Cancer, Solid Tumors | Full-length Protein for Ternary Complex Formation (Need HEK293-expressed native folding); Ubiquitination assays. |
| Small Molecule (Stabilizer) | Academic/Biotech Consortiums | Solid Tumors (Breast, Colon) | PPI Assay (Need high-purity WT proteins for SPR). |
| Small Molecule (DNA-binding inhibitor) | Early-stage discovery programs | Glioblastoma, CRPC | DNA-binding Mutant vs. WT Selectivity Assay (Need purified domain proteins). |
| Gene Therapy (HBP1 restoration) | Viral vector platforms, Emerging startups | Solid Tumors (localized), Refractory Cancers | Functional Overexpression Validation (Need high-titer Lentivirus/ORF). |
| PPI Disruptors (AR-HBP1) | Andrology/Oncology hybrids | CRPC, Breast Cancer | Co-IP Grade Antibodies and Full-length Co-expression Systems. |